Search the Newsreel

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

Zenas BioPharma (NASDAQ:ZBIO) experienced a 6.6% stock price drop after reporting disappointing quarterly earnings, with an EPS of $(1.77) against an estimated $(1.12) and revenue of $1 million against a $15 million forecast. Despite the earnings miss, analysts generally maintain a "Moderate Buy" rating …

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary

Zenas BioPharma, Inc. (ZBIO) reported its financial results for the quarter ended 2026, showing revenue of $1M and a net loss of ($111.46M), with a diluted loss per share of ($1.77). These figures represent a significant decrease in revenue and an increase in net …

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com

This article is a brief financial announcement from Investing.com, stating that Zenas Biopharma Inc. filed a Form 8K on August 13th. The filing is related to the company's financial activities and includes the stock symbol ZBIO, which showed a -6.68% change. The content primarily …

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss

Zenas BioPharma (ZBIO) announced a Q2 loss of $1.77 per share, which is significantly wider than FactSet's estimated loss of $1.12 per share. The company reported Q2 revenue of $1.0 million. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on autoimmune diseases with lead …

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma announced its second quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of the obexelimab BLA for IgG4-RD with a PDUFA date of May 27, 2027. The company also reported positive Phase 3 INDIGO trial results for obexelimab, …

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss

Zenas BioPharma (ZBIO) reported a second-quarter 2026 net loss of $111.5 million on $1.0 million in revenue, an increase from a $52.2 million net loss in the prior-year quarter. The company ended the quarter with $673.9 million in cash and investments, and its biologics …

Zenas BioPharma, Inc. (ZBIO) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 16, 2025

Levi & Korsinsky is urging investors who suffered losses in Zenas BioPharma, Inc. (ZBIO) to contact them before June 16, 2025, regarding a potential lawsuit. The lawsuit alleges that Zenas BioPharma made false statements about its ability to fund operations following its September 2024 …

Zenas Biopharma Inc (ZBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday

Zenas BioPharma (ZBIO) is expected to announce its Q2 2026 earnings before market open on Tuesday, August 11th. Analysts forecast a loss of $1.12 per share on $15 million in revenue, following a Q1 loss of $1.46 per share which slightly beat estimates. The …

Levi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025

Levi & Korsinsky is urging shareholders of Zenas BioPharma, Inc. (ZBIO) to act before the lead plaintiff deadline of June 16, 2025, in a lawsuit alleging that the company made false statements regarding its financial runway following its September 2024 IPO. The lawsuit claims …

Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Over Securities Violations - Contact Levi & Korsinsky Today

Levi & Korsinsky, LLP has filed a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities during its September 2024 IPO. The lawsuit alleges that Zenas BioPharma materially overstated its ability to fund operations with existing cash and …

Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

Zenas Biopharma Inc (ZBIO) Financial Health: Profitability & Balance Sheet Analysis

Zenas Biopharma Inc (ZBIO) currently holds a robust financial score of 9.25, ranking 6th out of 384 in the Biotechnology & Medical Research industry, indicating strong financial health and high operating efficiency. Despite this, the company reported a significant year-over-year decrease of 100.00% in …

Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Zenas Biopharma Inc (ZBIO), noting its current valuation score of 6.94 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.61, while stating that P/B, P/S, and P/CF data have not been …

Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for Zenas Biopharma Inc (ZBIO). It states that the company has distributed a total of 0.00 USD in dividends over the past five years, indicating no recent dividend payouts. The page also displays current stock data, …

Exome Asset Management LLC Takes Position in Zenas BioPharma, Inc. $ZBIO

Exome Asset Management LLC has acquired 80,730 shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) worth approximately $1.58 million, representing a 0.13% stake. Other institutional investors have also increased their holdings in the company, while CEO Leon O. Moulder Jr. significantly boosted his direct ownership by …

ZBIO|Zenas Biopharma Inc|Price:30.390|Chg%:-0.600

Zenas Biopharma Inc. (ZBIO) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Its lead product candidate, obexelimab, is being developed for conditions like IgG4-RD, relapsing multiple sclerosis, and systemic lupus erythematosus. The article provides company details including its market price, …

Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO) Investors

Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO). The lawsuit is on behalf of individuals who purchased Zenas BioPharma securities related to its September 2024 IPO. The complaint alleges that the company overstated its …

ZBIO6353884 Bond Profile — Key Metrics

This article provides a bond profile for ZBIO6353884, a Zenas BioPharma, Inc. 2.5% bond maturing on April 1, 2032. It details key metrics such as the issuer, issue date, maturity date, outstanding amount, face value, and coupon rate. Zenas BioPharma, Inc. is described as …

ZBIO6353884 Bond Risk Profile

This article provides a risk profile for the Zenas BioPharma, Inc. 2.5% 01-APR-2032 bond, identified as ZBIO6353884. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. The profile also mentions …

ZBIO6353884 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Zenas BioPharma, Inc. (ZBIO6353884) bond, detailing its 2.5% interest rate. It highlights that the next interest payment is scheduled for October 1, 2026, and offers an overview of the bond's payment structure and other key data. …

New Zenas hires receive stock awards vesting through 2030

Zenas BioPharma (Nasdaq: ZBIO) announced inducement equity awards for new employees, comprising 35,750 non-qualified stock options and 79,050 Restricted Stock Units (RSUs) under its 2026 Inducement Plan. The stock options vest over four years with a 10-year term, an exercise price of $29.41, while …

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees

Zenas BioPharma granted stock options and restricted stock units (RSUs) to new employees as an inducement to employment, aligning with Nasdaq rules and aiming to attract and retain top talent. These grants, including options for 35,750 shares and 79,050 RSUs, vest over four years …

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma announced inducement grants of non-qualified stock options and restricted stock units to new employees on July 15, 2026, as an incentive for their employment. The grants, made under Nasdaq Listing Rule 5635(c)(4), involve 35,750 shares of common stock options with an exercise …

Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says

Wedbush reiterated its Outperform rating on Zenas BioPharma despite a bear case suggesting overvaluation of its lead asset, obexelimab. The firm believes the bear case overlooks obexelimab's significant commercial potential, especially in a market where other treatments have faced challenges. Wedbush expects further data …

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.2% - Time to Buy?